Opioid Induced Constipation Treatment Market Attractive Growth Opportunities 2016–2024

Google+ Pinterest LinkedIn Tumblr +

Opioids are medications that work on opioid receptors in order to generate morphine-like effects. These are mainly used therapeutically to relieve pain and are often abused by individuals addicted to them. Opioids comprises opiates, a conventional name that points to drugs that are derivatives of opium, including morphine. Constipation means bowel actions that are sporadic or hard to go by. The fecal matter is often dry and hard. Some of the other symptoms include bloating, abdominal pain, and feeling the same as if the person has not passed bowels completely. Difficulties from constipation include anal fissure, fecal impaction, or hemorrhoids. Opioid-induced constipation is one of the most prevalent adverse effects connected with long-time use of opioids, which have a detrimental impact on the quality of life of the individual. The emblematic symptoms related to opioid-induced constipation are feeling hard and dry stools, distention and bulged abdomen, lethargy, loss of appetite, and painful defecation. Increasing consumption of opioids for myriad maladies is in turn leading to increasing prevalence of opioid-induced constipation, consequently fueling growth of the opioid induced constipation treatment market. The fresh approval of medicines for treatment of opioid-induced constipation has led to the emergence of various therapeutic approaches.

Request for complete TOC of this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/202

According to a report by National Center for Biotechnology Information, chronic pain is a persistent pain that lingers for 3 months or more. The occurrence of chronic pain in the population is 10–15%. In individuals with chronic non-cancer pain, the commonness of opioid induced constipation varies from 41% to 81%. The common sign for opioid use in non-cancer pain is muskoskeletal pain such as degenerative joint disease, headache back pain, and fibromyalgia. In the current scenario, around 4% of adults in the U.S. undergo chronic opioid therapy. The Centers for Disease Control and Prevention (CDC) projected that excessive and unregulated prescription of opioids by healthcare providers is one of the key reasons for opioid-related overdoses. Around 90% of individuals suffering from moderate to severe pain are prescribed opioids.

Increasing prevalence of opioid induced constipation and increase in chronic non-cancer pain to drive growth of overall opioid induced constipation treatment market

Prevalence of opioid induced constipation is rising considerably. According to the American Academy of Pain Medicine (AAPM), around 100 million patients in the U.S. suffered from opioid induced constipation in 2013. Furthermore, AAPM also estimated that the number of occurrences would rise, owing to the increase in the number of individuals taking opioid drugs. There is a growing responsiveness towards the availability of a large array of opioid drugs. This will encourage the patients to resort to using these drugs to treat chronic pains. The rising number of opioid induced constipation patients, particularly in the North America region is likely to drive the growth of the overall opioid induced constipation treatment industry. The regional market is projected to grow at a considerable rate due to the presence of large number of people who use opioid drugs. This is owing to high prevalence of disease associated with chronic pain in this region.

Some of the major companies operating in the opioid induced constipation treatment market in the current scenario are Daewoong Co. Ltd., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Cosmo Pharmaceuticals, AstraZeneca plc, Abbott Laboratories, Valeant Pharmaceuticals, C.B. Fleet Company, Inc., and Bayer AG.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/202

Opioid induced constipation treatment market Taxonomy

On the basis of method of administration, the global market is classified into: Subcutaneous Injection, Oral,.

On the basis of drug, the global market is classified into: Lubiprostone, Naloxegol, Docusate Sodium, Methylnaltrexone Bromide, Others ,.

On the basis of distribution channel, the global opioid induced constipation market is classified into: Hospital Pharmacies, Independent Pharmacies, Others,.

Rising number of patients using illegal medicines and deferred use of opioids in the therapy of chronic pain are some of the key factors driving growth of the opioid induced constipation (OIC) treatment market. Moreover, it has been observed that the untapped market for advantageous, successful and safe therapeutic solutions in OIC drug is extensive and developing at a fast pace, especially in developed regions.

Share.

About Author

Is a technology enthusiast, who has amassed a wide range of experience in the industry at a very young age. His extensive background of computer software and programming and proclivity to be up-to-date with the latest of technology upgrades and launches, helps him deliver the most intriguing and trending tech news. Contact Author

Comments are closed.